Attenuation of Glutamate-Induced Excitotoxicity by Withanolide-A in Neuron-Like Cells: Role for PI3K/Akt/MAPK Signaling Pathway
Overview
Neurology
Affiliations
Glutamate-induced excitotoxicity is one of the major underlying mechanisms for neurodegenerative diseases. Efforts are being made to treat such conditions with an array of natural compounds that can modulate the release of glutamate or the underlying mechanisms associated with it. Withania somnifera extract has potent pharmacologic activity similar to that of Korean Ginseng tea and is used to treat several neuronal disorders. However, to date, little efforts have been made to evaluate individual constituents of this plant for neurodegenerative disorders. Present study was carried out to investigate withanolide-A, one of the active constituents of Withania somnifera against glutamate-induced excitotoxicity in retinoic acid differentiated Neuro2a neuroblastoma cells. The results indicated that glutamate treatment for 2 h induced death in cells that was significantly attenuated by pre-treatment with MK-801 (specific NMDA receptor antagonist) and different concentrations of withanolide-A. Withanolide-A abated the glutamate-induced influx of intracellular calcium and excessive ROS production significantly. Further on, glutamate treatment resulted in increased levels of pro-apoptotic and decreased levels of anti-apoptotic proteins, and these protein levels were normalized by various doses of withanolide-A. All of these protective effects were partly due to inhibition of MAPK family proteins and activation of PI3K/Akt signaling. Thus, our results suggest that withanolide-A may serve as potential neuroprotective agent.
Nair A, Briget Kuriakose B, Biju A, Surendran S, Sudheesh M, Lakshmi P J Ayurveda Integr Med. 2025; 16(1):101041.
PMID: 39799838 PMC: 11773069. DOI: 10.1016/j.jaim.2024.101041.
Moharram F, Hamed F, El-Sayed E, Mohamed S, Ahmed A, Elgayed S Heliyon. 2024; 10(20):e39207.
PMID: 39640788 PMC: 11620252. DOI: 10.1016/j.heliyon.2024.e39207.
Neuroprotective effects of ellorarxine in neuronal models of degeneration.
Kouchmeshky A, Whiting A, McCaffery P Front Neurosci. 2024; 18:1422294.
PMID: 39376539 PMC: 11456694. DOI: 10.3389/fnins.2024.1422294.
Chowdhury K, Holden M, Wiley M, Suppiramaniam V, Reed M Cells. 2024; 13(13.
PMID: 38994982 PMC: 11240741. DOI: 10.3390/cells13131130.
Pal R, Mukherjee S, Khan A, Nathani M, Maji S, Tandey R Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9367-9415.
PMID: 38985312 DOI: 10.1007/s00210-024-03266-6.